(Q48417717)

English

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102).

scientific article published in October 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain: high rate of thromboembolic events (CALGB 500102). (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

0 references

thromboembolism

1 reference

based on heuristic

inferred from title

0 references

metastatic melanoma

1 reference

based on heuristic

inferred from title

Cancer and Leukemia Group B

7

object named as

Cancer and Leukemia Group B

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

author name string

Susan E Krown

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Donna Niedzwiecki

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Wen-Jen Hwu

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Lydia Hodgson

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Alan N Houghton

5

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Frank G Haluska

6

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

language of work or name

0 references

publication date

1 October 2006

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

107

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

8

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

1883-1890

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

Complications of therapy for venous thromboembolic disease in patients with brain tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

21 January 2018

Temozolomide plus thalidomide in patients with brain metastases from melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Gamma Knife radiosurgery for intracranial metastatic melanoma: an analysis of survival and prognostic factors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of temozolomide-based chemotherapy in patients with cerebral metastases from melanoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of temozolomide on central nervous system relapse in patients with advanced melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Thalidomide is an inhibitor of angiogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer-associated thrombosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Cancer and thromboembolic disease: pathogenic mechanisms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Management of venous thromboembolism in patients with primary and metastatic brain tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Thromboembolic complications after perioperative chemotherapy in women with early breast cancer: a European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Arterial thrombosis associated with adjuvant chemotherapy for breast carcinoma: a Cancer and Leukemia Group B Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Blood coagulation during adjuvant epirubicin/cyclophosphamide chemotherapy in patients with primary operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five-drug chemotherapy regimen. A study of 159 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Antitumor activity of thalidomide in refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Thromboembolic events during treatment with thalidomide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Deep venous thrombosis and thalidomide therapy for multiple myeloma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy of venous thromboembolism in patients with brain metastases

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

The management of thromboembolic disease in patients with central nervous system malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22239

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.22239

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/16986123

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48417717&oldid=2043643426"